Company: KNRX
Filing Date: 2025-09-02
Form Type: F-1/A
Source: 0001493152-25-012564
Chunk: 94

Company: KNOREX LTD.
Filing Date: 2025-09-02
Form: F-1/A
Chunk 94
---
0 million, a decrease of US$0.2 million in deferred revenue, which was offset by non-cash expenses of depreciation, amortization of discount on debt instrument, amortization of capitalized software development costs, and provision of credit losses of approximately US$0.7 million, an increase of US$1.0 million in accounts payable; an increase of US$0.6 million in other payables and accrued liabilities as a result of increased accrued payroll and professional fees, net of non-cash conversion of accrued interest of US$0.2 million into our ordinary shares; a decrease of US$0.1 million in accounts receivable due to our timely collections, a decrease of US$0.1 million in prepaid expenses and other current assets as a result of decreased security deposits, prepayments to vendors.

| 50 |

Investing Activities

Net cash used in investing activities was approximately US$867,000 for the year ended December 31, 2024, which was primarily attributable to the purchase of office equipment of approximately US$13,000 and capitalized software development costs of approximately US$0.9 million.

Net cash used in investing activities was approximately US$878,000 for the year ended December 31, 2023, which was primarily attributable to the purchase of office equipment of approximately US$2,000 and capitalized software development costs of approximately US$0.9 million.

Financing Activities

Net cash provided by financing activities was US$5.2 million for the year ended December 31, 2024, which was mainly attributable to the proceeds from exercise of warrants of US$1.3 million, proceeds from convertible notes of US$1.9 million, proceeds from short-term loan- third parties of US$2.4 million, proceeds from short-term loan- related parties of US$0.3 million, and offset by the repayments of long-term bank loans of US$0.5 million and payments of short-term loan – third parties of approximately US$0.2 million.

Net cash provided by financing activities was US$7.8 million for the year ended December 31, 2023, which was mainly attributable to the issuance of ordinary shares of US$8.2 million and the proceeds from exercise of warrants of US$0.5 million and offset by the repayments of long-term bank loans of US$0.5 million and payments of deferred offering costs of US$0.4 million.

Capital Expenditures

We made capital expenditures of